Shehnaaz Suliman sold $465k of TXG
director at 10x Genomics, Inc.. 5,723 shares at an average of $81.19, traded Sep 22, 2026, filed Sep 24, 2026.
Score components
- +15RoleDirector
- +17Trade size$465k at market
- +5Share of holdings soldSold 19% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-26-000422, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -292 | $78.20 | $23k | 29,223 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -614 | $79.51 | $49k | 28,609 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,325 | $80.82 | $107k | 27,284 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -2,270 | $81.67 | $185k | 25,014 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,222 | $82.28 | $101k | 23,792 | 18 d ago |
Related signals
Other insiders at 10x Genomics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | 10x Genomics, Inc. | Serge Saxonov Chief Executive Officer | $2.0M 25,000 shares | -2% | |
| 47Moderate | 10x Genomics, Inc. | Adam Taich Chief Financial Officer | $3.0M 46,388 shares | -13% | |
| 48Moderate | 10x Genomics, Inc. | John R Stuelpnagel director | $1.2M 20,000 shares | -6% | |
| 40Moderate | 10x Genomics, Inc. | Benjamin J. Hindson See Remarks | $103k 7,486 shares | -2% | |
| 51Moderate | 10x Genomics, Inc. | Adam Taich Chief Financial Officer | $308k 22,315 shares | -7% | |
| 51Moderate | 10x Genomics, Inc. | Serge Saxonov Chief Executive Officer | $129k 9,348 shares | -1% | |
| 43Moderate | 10x Genomics, Inc. | Adam Taich Chief Financial Officer | $34k 4,044 shares | -1% | |
| 37Weak | 10x Genomics, Inc. | Benjamin J. Hindson See Remarks | $62k 7,485 shares | -2% | |
| 49Moderate | 10x Genomics, Inc. | Serge Saxonov Chief Executive Officer | $78k 9,343 shares | -1% | |
| 7Weak | 10x Genomics, Inc. | Serge Saxonov Chief Executive Officer | $84k 7,942 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.